Abstract
Background and Aims: The risk and benefit of Glycoprotein IIb/IIIa inhibitors (GPI) use in combination with dual anti-platelet therapy (DAPT) especially the newer oral P2Y12 inhibitors in ST-Elevation Myocardial Infarction (STEMI) remain unassessed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
